Disclosures for "Efficacy and Safety of ES-481, a Novel TARP Inhibitor, in Drug-resistant Epilepsy: A Double-blind Randomized Placebo Controlled Phase IIa Trial"
-
The institution of Prof. O'Brien has received research support from Eisai. The institution of Prof. O'Brien has received research support from UCB. The institution of Prof. O'Brien has received research support from BioGen. The institution of Prof. O'Brien has received research support from ES Theraputics. The institution of an immediate family member of Prof. O'Brien has received research support from Epidarex.
-
The institution of Dr. Foster has received research support from Monash University Bridging Postdoctoral Fellowship. The institution of Dr. Foster has received research support from Sylvia and Charles Viertel Charitable Foundation. The institution of Dr. Foster has received research support from Brain Foundation (Australia). The institution of Dr. Foster has received research support from Australian Epilepsy Research Fund. The institution of Dr. Foster has received research support from LivaNova. The institution of Dr. Foster has received research support from Lundbeck Australia.
-
Ms. Millist has nothing to disclose.
-
Mr. Germaine has nothing to disclose.
-
Mrs. Chamorro has nothing to disclose.
-
Miss Roberts has nothing to disclose.
-
Dr. Nicolo has nothing to disclose.
-
Mr. Sean has nothing to disclose.
-
The institution of Dr. Perucca has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Chiesi. The institution of Dr. Perucca has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. The institution of Dr. Perucca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. The institution of Dr. Perucca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Perucca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for LivaNova. The institution of Dr. Perucca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Chiesi. The institution of Dr. Perucca has received research support from NHMRC. The institution of Dr. Perucca has received research support from Epilepsy Foundation. The institution of Dr. Perucca has received research support from Royal Australasian College of Physicians. The institution of Dr. Perucca has received research support from Melbourne Health. The institution of Dr. Perucca has received research support from Monash University. The institution of Dr. Perucca has received research support from Epilepsy Foundation . The institution of Dr. Perucca has received research support from Victorian Medical Research Acceleration Fund. The institution of Dr. Perucca has received research support from Sanming Project Grant, Shenzhen government. The institution of Dr. Perucca has received research support from Brain Australia. The institution of Dr. Perucca has received research support from Medical Research Future Fund. The institution of Dr. Perucca has received research support from Weary Dunlop Medical Research Foundation. The institution of Dr. Perucca has received research support from Norman Beischer Medical Research Foundation. The institution of Dr. Perucca has received research support from NHMRC. The institution of Dr. Perucca has received research support from Austin Medical Research Foundation.
-
Dr. Mullen has nothing to disclose.
-
Ms. Robinson has nothing to disclose.
-
Miss Wharrie has nothing to disclose.
-
Mrs. Walsh has nothing to disclose.
-
The institution of Dr. Reutens has received research support from Australian Research Council. The institution of Dr. Reutens has received research support from Siemens Health Care. The institution of Dr. Reutens has received research support from Vivazone Pty Ltd. Dr. Reutens has received intellectual property interests from a discovery or technology relating to health care.
-
Mrs. Irwin has nothing to disclose.
-
-
Dr. Niecestro has received personal compensation for serving as an employee of ES Therapeutics. Dr. Niecestro has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Cyprium Therapeutics. Dr. Niecestro has received research support from ES Therapeutics.